X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ZACKS.COM - All Stories - 11/07/2024 13:02

United Therapeutics (UTHR) Completes Enrolment in IPF Study

United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.

Articles similaires

Sorry! Image not available at this time

ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection

wn.com - 15/Oct 18:51

NEWTON, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive...

Sorry! Image not available at this time

ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection

wn.com - 15/Oct 18:51

NEWTON, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive...

Sorry! Image not available at this time

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

wn.com - 13:50

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of...

Sorry! Image not available at this time

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

wn.com - 18/Oct 19:21

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a...

Sorry! Image not available at this time

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

wn.com - 18/Oct 19:21

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a...

Sorry! Image not available at this time

Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation

mangaloremirror.com - 13/Oct 16:55

Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic...

Sorry! Image not available at this time

Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation

mangaloremirror.com - 13/Oct 16:55

Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic...

Sorry! Image not available at this time

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

drugs.com - 15/Oct 21:10

RAHWAY, N.J.--(BUSINESS WIRE) October 15, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the...

Sorry! Image not available at this time

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

drugs.com - 15/Oct 21:10

RAHWAY, N.J.--(BUSINESS WIRE) October 15, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the...

Sorry! Image not available at this time

SONEX HEALTH ACHIEVES ENROLLMENT TARGET IN LARGEST-EVER MULTI-ARM U.S. STUDY ON PATIENTS TREATED WITH CARPAL ...

wn.com - 16/Oct 19:55

The landmark MISSION clinical registry is collecting real-world data across the United States and rapidly enrolled more than 1,300 patients in an...

Les derniers communiqués